JP7475811B2 - 遺伝子に基づく炎症性腸疾患の診断 - Google Patents
遺伝子に基づく炎症性腸疾患の診断 Download PDFInfo
- Publication number
- JP7475811B2 JP7475811B2 JP2018560186A JP2018560186A JP7475811B2 JP 7475811 B2 JP7475811 B2 JP 7475811B2 JP 2018560186 A JP2018560186 A JP 2018560186A JP 2018560186 A JP2018560186 A JP 2018560186A JP 7475811 B2 JP7475811 B2 JP 7475811B2
- Authority
- JP
- Japan
- Prior art keywords
- allele
- pos
- snp
- nuclear
- ibd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims description 171
- 108090000623 proteins and genes Proteins 0.000 title description 165
- 238000003745 diagnosis Methods 0.000 title description 3
- 108700028369 Alleles Proteins 0.000 claims description 257
- 238000000034 method Methods 0.000 claims description 100
- 239000000523 sample Substances 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 38
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 36
- 239000002751 oligonucleotide probe Substances 0.000 claims description 36
- 238000003205 genotyping method Methods 0.000 claims description 31
- 238000009396 hybridization Methods 0.000 claims description 31
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 21
- 208000011231 Crohn disease Diseases 0.000 claims description 21
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 21
- 238000002493 microarray Methods 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 8
- 210000000349 chromosome Anatomy 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 6
- 238000003752 polymerase chain reaction Methods 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 5
- 238000001712 DNA sequencing Methods 0.000 claims description 2
- 238000003559 RNA-seq method Methods 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 238000003753 real-time PCR Methods 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 72
- 201000010099 disease Diseases 0.000 description 66
- 238000001514 detection method Methods 0.000 description 43
- 102100029877 F-actin-uncapping protein LRRC16A Human genes 0.000 description 36
- 101000793823 Homo sapiens F-actin-uncapping protein LRRC16A Proteins 0.000 description 36
- 230000002068 genetic effect Effects 0.000 description 32
- 108010033040 Histones Proteins 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 28
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 26
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 26
- 101000876829 Homo sapiens Protein C-ets-1 Proteins 0.000 description 26
- 102100035251 Protein C-ets-1 Human genes 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 102000054766 genetic haplotypes Human genes 0.000 description 23
- 101000653374 Homo sapiens Methylcytosine dioxygenase TET2 Proteins 0.000 description 18
- 102100030803 Methylcytosine dioxygenase TET2 Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 239000000975 dye Substances 0.000 description 16
- 238000012100 gene-based analysis Methods 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 241000218645 Cedrus Species 0.000 description 10
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 10
- 102100037475 General transcription factor II-I repeat domain-containing protein 2B Human genes 0.000 description 10
- 101000902096 Homo sapiens Disks large homolog 4 Proteins 0.000 description 10
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 description 10
- 101001026144 Homo sapiens General transcription factor II-I repeat domain-containing protein 2B Proteins 0.000 description 10
- 101001047515 Homo sapiens Lethal(2) giant larvae protein homolog 1 Proteins 0.000 description 10
- 101001090551 Homo sapiens Proline-rich protein 5-like Proteins 0.000 description 10
- 101000804728 Homo sapiens Protein Wnt-2b Proteins 0.000 description 10
- 101000611192 Homo sapiens Trinucleotide repeat-containing gene 6B protein Proteins 0.000 description 10
- 101000788658 Homo sapiens Zinc fingers and homeoboxes protein 3 Proteins 0.000 description 10
- 102100022956 Lethal(2) giant larvae protein homolog 1 Human genes 0.000 description 10
- 102100035278 Pendrin Human genes 0.000 description 10
- 102100034734 Proline-rich protein 5-like Human genes 0.000 description 10
- 102100035289 Protein Wnt-2b Human genes 0.000 description 10
- 108091006507 SLC26A4 Proteins 0.000 description 10
- 108091006277 SLC5A1 Proteins 0.000 description 10
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 description 10
- 102100040244 Trinucleotide repeat-containing gene 6B protein Human genes 0.000 description 10
- 102100025095 Zinc fingers and homeoboxes protein 3 Human genes 0.000 description 10
- 230000009466 transformation Effects 0.000 description 10
- 102100027138 Butyrophilin subfamily 3 member A1 Human genes 0.000 description 9
- 101000984934 Homo sapiens Butyrophilin subfamily 3 member A1 Proteins 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000012408 PCR amplification Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000002596 correlated effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000012321 colectomy Methods 0.000 description 6
- 206010009887 colitis Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000007850 fluorescent dye Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100027155 Butyrophilin subfamily 3 member A2 Human genes 0.000 description 5
- 101000984917 Homo sapiens Butyrophilin subfamily 3 member A2 Proteins 0.000 description 5
- 101100480850 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) TDA3 gene Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000010197 meta-analysis Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000005022 packaging material Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000013507 mapping Methods 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102100025971 F-actin-capping protein subunit alpha-2 Human genes 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 101000933166 Homo sapiens F-actin-capping protein subunit alpha-2 Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000013488 ordinary least square regression Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 2
- 241000282421 Canidae Species 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000157302 Bison bison athabascae Species 0.000 description 1
- 102100027154 Butyrophilin subfamily 3 member A3 Human genes 0.000 description 1
- 108010017533 Butyrophilins Proteins 0.000 description 1
- 102000004555 Butyrophilins Human genes 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100029875 Capping protein, Arp2/3 and myosin-I linker protein 3 Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000035131 DNA demethylation Effects 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102100022653 Histone H1.5 Human genes 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000984916 Homo sapiens Butyrophilin subfamily 3 member A3 Proteins 0.000 description 1
- 101000793839 Homo sapiens Capping protein, Arp2/3 and myosin-I linker protein 3 Proteins 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 101000899879 Homo sapiens Histone H1.5 Proteins 0.000 description 1
- 101001067880 Homo sapiens Histone H4 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 108030004080 Methylcytosine dioxygenases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 1
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000001509 acute urate nephropathy Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000001243 pseudopodia Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000019808 uric acid nephrolithiasis Diseases 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022044738A JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339357P | 2016-05-20 | 2016-05-20 | |
| US62/339,357 | 2016-05-20 | ||
| PCT/US2017/033625 WO2017201461A1 (en) | 2016-05-20 | 2017-05-19 | Diagnosis of inflammatory bowel disease based on genes |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044738A Division JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A Division JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516375A JP2019516375A (ja) | 2019-06-20 |
| JP2019516375A5 JP2019516375A5 (enExample) | 2020-06-18 |
| JP7475811B2 true JP7475811B2 (ja) | 2024-04-30 |
Family
ID=60326226
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560186A Active JP7475811B2 (ja) | 2016-05-20 | 2017-05-19 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2022044738A Active JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A Pending JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022044738A Active JP7392020B2 (ja) | 2016-05-20 | 2022-03-18 | 遺伝子に基づく炎症性腸疾患の診断 |
| JP2023213224A Pending JP2024037945A (ja) | 2016-05-20 | 2023-12-18 | 遺伝子に基づく炎症性腸疾患の診断 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11549146B2 (enExample) |
| EP (1) | EP3458466B1 (enExample) |
| JP (3) | JP7475811B2 (enExample) |
| KR (4) | KR102481305B1 (enExample) |
| CN (2) | CN109476698B (enExample) |
| WO (1) | WO2017201461A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| JP7082945B2 (ja) | 2016-03-17 | 2022-06-09 | シーダーズ―シナイ メディカル センター | Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法 |
| KR102481305B1 (ko) * | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| WO2020232125A1 (en) | 2019-05-14 | 2020-11-19 | Prometheus Biosciences, Inc. | Tl1a patient selection methods, systems, and devices |
| EP4171632A2 (en) * | 2020-06-26 | 2023-05-03 | Pfizer Inc. | Methods of treating inflammatory bowel disease with tl1a antibodies |
| WO2022103961A1 (en) * | 2020-11-13 | 2022-05-19 | Prometheus Biosciences, Inc. | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| CN115851911B (zh) * | 2022-11-25 | 2025-10-24 | 南京鼓楼医院 | 一种用于鉴别狼疮性肾炎的尿液外泌体tsRNA标志物和探针及其应用 |
| WO2024148218A2 (en) * | 2023-01-06 | 2024-07-11 | Prometheus Biosciences, Inc. | Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106451A2 (en) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| WO2014186750A2 (en) | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
| JP2015502740A (ja) | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443421A (en) | 1982-03-16 | 1984-04-17 | Occidental Chemical Corporation | Process for removing particulate impurities from aqueous phosphoric acid |
| EP0191102B1 (en) | 1984-08-27 | 1989-01-04 | Toray Industries, Inc. | Solid-liquid separating apparatus |
| US5000850A (en) | 1986-09-10 | 1991-03-19 | Engelhard Corporation | Apparatus for dewatering an aqueous clay suspension |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7357927B2 (en) | 1996-03-12 | 2008-04-15 | Human Genome Sciences, Inc. | Death domain containing receptors |
| JP2002521062A (ja) * | 1998-07-25 | 2002-07-16 | アストラゼネカ・アクチエボラーグ | ヒトニューロキニン１レセプター遺伝子における遺伝子多形性および疾病の診断および処置におけるその使用 |
| JP2004194534A (ja) | 2002-12-17 | 2004-07-15 | Sumitomo Pharmaceut Co Ltd | 炎症性腸疾患疾患マーカーおよびその利用 |
| WO2005040416A1 (en) * | 2003-10-06 | 2005-05-06 | Novartis Ag | Use of genetic polymorphisms that associate with efficacy of treatment of inflammatory disease |
| AU2005300688B2 (en) | 2004-11-03 | 2012-02-02 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| JP5065253B2 (ja) | 2005-05-06 | 2012-10-31 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１モノクローナル抗体とその使用法 |
| WO2006127900A2 (en) | 2005-05-25 | 2006-11-30 | Biogen Idec Ma Inc. | Tl1a in the treatment of disease |
| EP1963534A2 (en) * | 2005-12-19 | 2008-09-03 | Genizon Biosciences Inc. | Genemap of the human gene associated with crohn's disease |
| EP2097538A4 (en) | 2006-12-07 | 2011-11-30 | Switchgear Genomics | TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS |
| US20110217310A1 (en) * | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| CA2676227A1 (en) * | 2007-02-12 | 2008-08-21 | The Johns Hopkins University | Early detection and prognosis of colon cancers |
| WO2008106579A2 (en) | 2007-02-28 | 2008-09-04 | Cedars-Sinai Medical Center | The role of il-12, il-23 and il-17 receptors in inflammatory bowel disease |
| US20150376707A1 (en) | 2007-05-18 | 2015-12-31 | Cedars-Sinai Medical Center | Methods of diagnosing and treating inflammatory bowel disease |
| US8118175B2 (en) | 2007-07-18 | 2012-02-21 | Siemens Industry, Inc. | Venting device for a disc filter |
| WO2009039244A2 (en) * | 2007-09-18 | 2009-03-26 | Genizon Biosciences Inc. | Genemap of the human genes associated with crohn's disease |
| WO2009052512A2 (en) * | 2007-10-19 | 2009-04-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| CA2705292C (en) | 2007-11-13 | 2016-06-21 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against tl1a |
| NZ710443A (en) * | 2008-08-12 | 2019-03-29 | Zinfandel Pharmaceuticals Inc | Method of identifying disease risk factors |
| CN102165315B (zh) | 2008-08-29 | 2014-06-18 | 森托科尔奥索生物科技公司 | 用于使用20基因群组评估及治疗溃疡性结肠炎和相关疾病的标记物和方法 |
| JP2010088432A (ja) | 2008-09-09 | 2010-04-22 | Kansetsu Saisei Kenkyusho:Kk | Ｔｎｆ阻害薬治療による有効性・副作用発現に関する多型、およびその利用 |
| US9580752B2 (en) | 2008-12-24 | 2017-02-28 | Cedars-Sinai Medical Center | Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy |
| CA2758531C (en) | 2009-04-14 | 2018-11-13 | Derren Barken | Inflammatory bowel disease prognostics |
| US20130136720A1 (en) | 2010-01-15 | 2013-05-30 | Cedars-Sinai Medical Center | Methods of using fut2 genetic variants to diagnose crohn's disease |
| EP2576838A4 (en) * | 2010-06-04 | 2019-05-15 | Nestec S.A. | METHOD FOR IMPROVING DIAGNOSIS OF INFLAMMATORY ENDURANCE |
| US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
| DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
| US9902996B2 (en) * | 2011-02-11 | 2018-02-27 | Cedars-Sinai Medical Center | Methods of predicting the need for surgery in crohn's disease |
| WO2012154987A1 (en) | 2011-05-10 | 2012-11-15 | Nestec Sa | Methods of disease activity profiling for personalized therapy management |
| EP2710147A1 (en) | 2011-05-18 | 2014-03-26 | Rheinische Friedrich-Wilhelms-Universität Bonn | Molecular analysis of acute myeloid leukemia |
| WO2012161856A1 (en) | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| AU2012261933B2 (en) | 2011-06-03 | 2017-06-15 | Xoma Technology Ltd. | Antibodies specific for TGF-beta |
| EP2812445A2 (en) * | 2012-02-10 | 2014-12-17 | Novo Nordisk A/S | Methods related to treatment of inflammatory diseases and disorders |
| EP3639841B1 (en) | 2013-03-27 | 2023-09-06 | Cedars-Sinai Medical Center | Treating fibrosis by inhibiting tl1a |
| AU2014331841B2 (en) | 2013-10-09 | 2020-03-12 | Cedars-Sinai Medical Center | Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease |
| EP3117011B1 (en) * | 2014-03-13 | 2020-05-06 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| JP2018512876A (ja) | 2015-04-22 | 2018-05-24 | ミナ セラピューティクス リミテッド | ｓａＲＮＡ組成物および使用方法 |
| WO2017147468A1 (en) | 2016-02-26 | 2017-08-31 | Nanotech Energy, Inc. | Methods, devices and systems for processing of carbonaceous compositions |
| KR102481305B1 (ko) * | 2016-05-20 | 2022-12-26 | 세다르스-신나이 메디칼 센터 | 유전자에 기반한 염증성 장 질환의 진단 |
| WO2018022982A1 (en) | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| SG11201903737PA (en) | 2016-10-26 | 2019-05-30 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| WO2018204764A1 (en) | 2017-05-05 | 2018-11-08 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| WO2020121618A1 (ja) | 2018-12-14 | 2020-06-18 | 株式会社フジクラ | フェルール、ファイバ付きフェルール及びファイバ付きフェルールの製造方法 |
-
2017
- 2017-05-19 KR KR1020227003985A patent/KR102481305B1/ko active Active
- 2017-05-19 KR KR1020247019512A patent/KR20240095363A/ko not_active Ceased
- 2017-05-19 US US16/303,033 patent/US11549146B2/en active Active
- 2017-05-19 EP EP17800279.6A patent/EP3458466B1/en active Active
- 2017-05-19 KR KR1020227044940A patent/KR20230003433A/ko not_active Ceased
- 2017-05-19 CN CN201780044934.7A patent/CN109476698B/zh active Active
- 2017-05-19 KR KR1020187037151A patent/KR20190016972A/ko not_active Ceased
- 2017-05-19 CN CN202311263442.0A patent/CN117286238A/zh active Pending
- 2017-05-19 JP JP2018560186A patent/JP7475811B2/ja active Active
- 2017-05-19 WO PCT/US2017/033625 patent/WO2017201461A1/en not_active Ceased
-
2022
- 2022-03-18 JP JP2022044738A patent/JP7392020B2/ja active Active
- 2022-12-09 US US18/063,931 patent/US20230366028A1/en active Pending
-
2023
- 2023-12-18 JP JP2023213224A patent/JP2024037945A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008106451A2 (en) | 2007-02-26 | 2008-09-04 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
| JP2015502740A (ja) | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
| WO2014186750A2 (en) | 2013-05-17 | 2014-11-20 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019516375A (ja) | 2019-06-20 |
| JP7392020B2 (ja) | 2023-12-05 |
| EP3458466A4 (en) | 2020-03-04 |
| EP3458466A1 (en) | 2019-03-27 |
| CN109476698B (zh) | 2023-10-17 |
| KR20240095363A (ko) | 2024-06-25 |
| KR20190016972A (ko) | 2019-02-19 |
| CN117286238A (zh) | 2023-12-26 |
| KR20230003433A (ko) | 2023-01-05 |
| KR102481305B1 (ko) | 2022-12-26 |
| KR20220025122A (ko) | 2022-03-03 |
| US11549146B2 (en) | 2023-01-10 |
| EP3458466B1 (en) | 2024-08-07 |
| JP2024037945A (ja) | 2024-03-19 |
| JP2022095688A (ja) | 2022-06-28 |
| WO2017201461A1 (en) | 2017-11-23 |
| CN109476698A (zh) | 2019-03-15 |
| US20230366028A1 (en) | 2023-11-16 |
| US20190194754A1 (en) | 2019-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7392020B2 (ja) | 遺伝子に基づく炎症性腸疾患の診断 | |
| EP2689036B1 (en) | Methods of diagnosing and treating intestinal granulomas and low bone density in inflammatory bowel disease | |
| US20100055700A1 (en) | Role of il-12, il-23 and il-17 receptors in inflammatory bowel disease | |
| US20100144903A1 (en) | Methods of diagnosis and treatment of crohn's disease | |
| US20110177969A1 (en) | The role of il17rd and the il23-1l17 pathway in crohn's disease | |
| US20100184050A1 (en) | Diagnosis and treatment of inflammatory bowel disease in the puerto rican population | |
| MX2008016524A (es) | Biomarcadores para la progresion de la enfermedad de alzheimer. | |
| WO2008144316A1 (en) | Blood biomarkers for psychosis | |
| US9305137B1 (en) | Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach | |
| US20180208988A1 (en) | Methods of diagnosis and treatment of inflammatory bowel disease | |
| US20200102610A1 (en) | Method for cerebral palsy prediction | |
| JP2020089370A (ja) | 抗精神病薬に基づく処置により誘導される錐体外路症状（ｅｐｓ）の発症を予測する方法 | |
| CA2946317A1 (en) | Methods of predicting medically refractive ulcerative colitis (mruc) requiring colectomy | |
| JP2006518206A (ja) | 処置中の自殺傾向を予測するための方法 | |
| US20120190698A1 (en) | Methods of predicting thiopurine response | |
| US20120041082A1 (en) | Methods of using smad3 and jak2 genetic variants to diagnose and predict inflammatory bowel disease | |
| CN119220666A (zh) | Chrm3基因多态性在阿托品易感近视人群诊断或筛查中的应用 | |
| AU2005250142B2 (en) | Biomarkers for the prediction of responsiveness to clozapine treatment | |
| WO2025189251A1 (en) | Diagnostic and prognostic signatures for sepsis | |
| Aus Kermanshah | Masoud Garshasbi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200507 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210506 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210806 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220318 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220318 |
|
| C11 | Written invitation by the commissioner to file amendments |
Free format text: JAPANESE INTERMEDIATE CODE: C11 Effective date: 20220404 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220506 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220509 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220527 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220601 |
|
| RD12 | Notification of acceptance of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7432 Effective date: 20230428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230428 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231218 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20240116 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240116 |
|
| RD14 | Notification of resignation of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7434 Effective date: 20240116 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240417 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7475811 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |